Acute Coronary Syndrome
AZD6140 plus aspirin assessed for safety, tolerability as antiplatelet therapy
Published in Drug Week, December 16th, 2005
The primary end point of the study was the incidence of total (major plus minor) bleeding events seen in patients taking AZD6140 or clopidogrel, which overall was 10.2% for the AZD6140 90 mg twice daily (BID) group, 10.2% for the AZD6140 180 mg BID group, and 9.2% for the clopidogrel 75 mg once daily (QD) group. Within these figures,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-12-16)
More Articles from Drug Week
- Diagnostics
Adding a bile acid sequestrant to statin therapy reported to reduce median hs-CRP levels - Drug Development
New drug application submitted for Toprol-XL and thiazide combination tablets for hypertension - Drug Development
U.S. FDA accepts supplemental application for Tysabri in multiple sclerosis - HIV/AIDS Therapy
U.S. FDA grants approval for new Kaletra tablet formulation for HIV patients - Pancreatic Cancer
Favorable 2-year survival data from phase II clinical trial of GVAX vaccine for pancreatic cancer - Acute Coronary Syndrome
New study finds enoxaparin to be at least as effective as unfractionated heparin in treating ACS - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
